Efficacy and comparative effectiveness of off-label use of atypical antipsychotics

Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone are atypical antipsychotics approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia and bipolar disorder. These drugs have been studied for off-label use in the following conditions: dementia and severe...

Full description

Main Author: Shekelle, Paul G.
Corporate Authors: Southern California Evidence-Based Practice Center/RAND., United States Agency for Healthcare Research and Quality
Format: eBook
Language:English
Published: Rockville, MD Agency for Healthcare Research and Quality 2007, [2007]
Series:Comparative effectiveness review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone are atypical antipsychotics approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia and bipolar disorder. These drugs have been studied for off-label use in the following conditions: dementia and severe geriatric agitation, depression, obsessive-compulsive disorder, posttraumatic stress disorder, and personality disorders. The atypicals have also been studied for the management of Tourette's syndrome and autism in children. The purpose of this report is to review the scientific evidence on the safety and effectiveness of such off-label uses
Item Description:Title from PDF title page (viewed on July 25, 2011). - "January 2007.". - "Contract No. 290-02-0003."